Malnutrition in Cirrhosis of the Liver

Overview

Cirrhosis is the endstage of chronic liver disease, characterised by fibrosis, nodular regeneration and loss of normal hepatic architecture. Even in the early compensated phase, many patients develop inadequate nutrient intake or absorption, and as the disease advances, malnutrition becomes highly prevalent. Studies estimate that 3070% of individuals with cirrhosis are malnourished, a figure that rises sharply in those awaiting liver transplantation.

Why Malnutrition Occurs in Cirrhosis

Multiple mechanisms act together:

• Reduced intake: Anorexia, early satiety from ascites, altered taste, alcohol use, and depression all limit food consumption.
• Malabsorption: Portal hypertension leads to intestinal edema and bacterial overgrowth, impairing absorption of carbohydrates, fats and fatsoluble vitamins.
• Impaired metabolism: The cirrhotic liver cannot store glycogen efficiently, causing early depletion of glucose stores and a switch to protein catabolism.
• Increased losses: Frequent diuretic therapy, paracentesis, and gastrointestinal bleeding increase loss of protein and micronutrients.
• Hormonal dysregulation: Elevated cytokines (TNF, IL6) and reduced insulinlike growth factor1 promote muscle breakdown.

Clinical Consequences

Malnutrition in cirrhosis is not a benign sideeffect; it directly worsens prognosis.

1. Reduced survival: Each 1% drop in body weight is associated with a 510% increase in 1year mortality.
2. Higher risk of complications: Infections, hepatic encephalopathy, variceal bleeding and hepatorenal syndrome occur more often.
3. Sarcopenia: Loss of skeletal muscle mass impairs functional status and limits eligibility for transplantation.
4. Poor wound healing: This affects surgical outcomes and favors postprocedure infections.

Assessment of Nutritional Status

Because traditional markers (e.g., serum albumin) are confounded by liver synthetic function, a combination of tools is recommended.

Screening should be performed at diagnosis and revisited every 36months or after decompensation events.

Management Strategies

Effective nutrition therapy blends dietary counseling, supplementation and, when needed, enteral or parenteral routes.

1. Energy and Protein Targets

• Energy: 3035kcal/kg/day (1.52 resting energy expenditure).
• Protein: 1.21.5g/kg/day; higher (up to 2g/kg) for those with sarcopenia.

2. Meal Timing

• Provide 34 small meals plus a latenight snack (approximately 30% of total calories).
• Complex carbohydrates with lowglycemic index reduce postprandial hyperinsulinemia.

3. Specific Nutrient Supplementation

• Branchedchain amino acids (BCAAs): Useful in hepatic encephalopathy and improve protein synthesis.
• Vitamin D: Deficiency is common; supplement to maintain serum 25OHD>30ng/mL.
• Fatsoluble vitamins (A, E, K): Give oral or IM preparations if levels are low.
• Zinc: 50mg elemental zinc daily may improve taste and ammonia metabolism.

4. Managing Ascites and Fluid Restrictions

Loop diuretics can increase sodium loss and reduce appetite. Combine sodium restriction (2g/day) with careful diuretic titration and consider diureticsparing agents (e.g., aldosterone antagonists) to minimise catabolism.

5. Enteral Nutrition (EN)

Indicated when oral intake is <75% of requirements for >5days. A nasogastric tube with a highprotein, energydense formula is preferred. Continuous overnight feeding can meet latenight caloric goals without overloading the stomach.

6. Parenteral Nutrition (PN)

Reserved for refractory cases where EN is not tolerated and the risk of malnutrition outweighs infection risk. Use shortterm PN (<2weeks) and monitor electrolytes, triglycerides and liver function closely.

7. Physical Activity

Combined resistance and aerobic exercise (35 sessions/week) preserves muscle mass, enhances insulin sensitivity, and improves quality of life.

8. Multidisciplinary Care

Optimal outcomes require coordination among hepatologists, dietitians, physiotherapists and transplant coordinators. Regular reevaluation ensures that nutritional interventions adapt to disease progression.